IFIH1 and interstitial lung disease: Among patients with RP-ILD, anti-MDA5-positivity was significantly associated with poor survival (57% at both 5 and 10 years) compared to the anti-MDA5-negative group (89% at both 5 and 10 years, P = 0.007) (Figure 2A).